Molecular follow-up of a preinvasive bronchial lesion treated by 13-cis-retinoic acid.
We report the result of the follow-up molecular analysis of a bronchial carcinoma in situ treated by 13-cis-retinoic acid, which relapsed 9 months after cessation of drug therapy. Loss of heterozygosity at 3p21 and 9p22 genomic sequences were assessed by polymerase chain reaction (PCR) after microdissection of the dysplastic epithelia. Despite a transient regression of the lesion to a lower grade with treatment, molecular analysis showed the persistence of a 3p and 9p deletion in all the bronchial biopsies taken in the same area during a 1 year follow-up, preceding by 9 months the recurrence of the carcinoma in situ. Our findings suggest that molecular follow-up analysis can help to assess the persistence of a malignant clone within a bronchial epithelium that displays a more benign phenotype under retinoid treatment on follow-up. Molecular analysis may be of great importance to evaluate the effects of chemoprevention and to determine the duration of such intervention in responder patients.
Thiberville
L
L
Institut National de la Santé et de la Recherche Medicale (Unite 295),Faculté de Medecine et de Pharmacie de Rouen, France.
Payne
P
P
Metayer
J
J
Vielkinds
J
J
LeRiche
J
J
Palcic
B
B
Lam
S
S
D001984:Bronchial Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D002278:Carcinoma in Situ / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D004273:DNA, Neoplasm / Q000032:analysis; D005500:Follow-Up Studies; D006801:Humans; D015474:Isotretinoin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness
D004273:DNA, Neoplasm; D015474:Isotretinoin